These biotech penny stocks are up as much as 333.9% so far this year, making them tempting to buy.
But this one stock is set to double your money with much less risk and is trading for less than $12 a share.
Here's why it's a better buy than penny stocks...
Start the conversation
Leave a Reply
Proteon Therapeutics stock crashed 70.71% to $2.90 in pre-market trading today after the company said a phase 3 trial of its chronic kidney disease treatment failed to meet the primary endpoint.
The trial results mark a major setback for the biotech company.
Start the conversation
Leave a Reply
The 21st Century Act seems to benefit patients by expediting the drug approval process, but it fails to address one key issue.
Start the conversation
Leave a Reply
The biotech sector is up nearly 16% over the last three months, handily beating the overall market's returns.
And the biotech sector will continue to stand out this year.
And we've got the best biotech ETF to buy before 2017...
The biotech sector has rebounded from its sharp sell-off, up 16% since June 27.
And as the comeback continues, this is the best investment to partake in the gains...
Start the conversation
Leave a Reply
When looking for the best biotech stocks to buy today, we've been targeting a brand-new subsector of the industry that is about to become a $25 billion market.
The company we're recommending today is global drug giant that has inked a partnership with a tech titan.
Start the conversation
Leave a Reply
The shifting currents in bioelectronics - a $25 billion market growing 10% per year - could move dollars your way.
Consider this sector leader. Up 12% since March, it's outperforming the S&P 500...
Start the conversation
Leave a Reply
The biotech sector is up more than 20% recently, making now a great time to invest.
That's why Money Morning Director of Tech & Venture Capital Michael A. Robinson just recommended one of the best biotech stocks to buy.
Here's more on this investment, which could return more than 50% in the next year...
Start the conversation
Leave a Reply
The following three tips let you get the biggest profits ever when investing in biotech stocks - if you do proper research and exercise discipline.
Use these to increase your chances of getting huge biotech gains in 2016.
Continue on to biotech stock tips here...
Start the conversation
Leave a Reply
Gilead Sciences Inc.'s Sovaldi was a real breakthrough in the fight against the chronic liver disease hepatitis C (HCV). The condition may show no symptoms for years after initial infection but can slowly become debilitating.
Hepatitis C affects as many as 200 million people worldwide, and before Sovaldi, the approved drug regimen could treat only about 50% of cases and could cause serious side effects. Treatment was generally long - 24 to 48 weeks - and arduous.
Sovaldi, on the other hand, could cure more than 90% of cases in a matter of weeks at a cost, in the United States, of around $94,000. The pricing caused controversy, but the drug proved transformative for HCV patients, their families, and doctors.
Sovaldi also proved a huge windfall for investors when it received FDA approval in 2013 and entered the pharmaceutical marketplace the following year.
So far, Gilead shareholders have seen a 2:1 split, several dividend payouts, and gains of more than 155% since 2013. Sales of Sovaldi and Gilead's other HCV drug, Harvoni, topped $12.5 billion in 2015 alone.
There's just one big, expensive problem...
Start the conversation
Leave a Reply
Biotech stocks have stalled in 2016 along with the broader markets, with the iShares Nasdaq Biotech ETF (Nasdaq: IBB) down 24.43% year to date.
Still, Money Morning Biotech Investing Specialist Ernie Tremblay says the sector will outperform in 2016. And he's pinpointed one foundational play that's already climbed 14% in the last five days.
But first, here's why biotech stocks are presenting a huge opportunity right now...
Sometimes Washington triggers a stock move that can hand us outsized gains. That's exactly what happened with Gilead Sciences Inc. (Nasdaq: GILD).
In March 2014, U.S. Rep. Henry Waxman (D-CA) lashed out at the cost of Gilead's newly approved Hepatitis C (HCV) drug, Sovaldi. Sovaldi runs $84,000, or $1,000 a pill.
But Waxman missed the obvious. Sovaldi (and its newer version Harvoni) cures 90% of HCV patients. That means patients can avoid the need for a liver transplant - an operation that runs $250,000 if an organ donor is found. And that price doesn't include antirejection drugs and antibiotics people must take for the rest of their lives.
Still, Gilead sold off on fears that its high cost would make Medicare look to another HCV drug maker with a less expensive solution. GILD stock lost 13% of its value in a matter of days.
Wall Street was dead wrong...
Medicare actually spent $4.6 billion on Hepatitis C treatments in the first six months of this year. That's almost as much as the agency spent in all of 2014. Gilead accounted for 66% of all covered prescriptions.
And since April 2014, Gilead has gained 66.5% - more than four times that of the S&P 500.
Start the conversation
Leave a Reply
Biotech ETFs have been the focus of many investors this week after Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) shares dropped more than 46% last week.
One biotech ETF with Valeant as a holding slumped 8.4% in the past three months, as VRX stock continues to fall.
Here are this week's need-to-know facts about the stock market, economy, Wall Street, and life-changing global events...
It's the numbers that count in this crazy world. They can tell stories that words sometimes can't.
Start the conversation
Leave a Reply
The S&P 500 has dropped 3.8% since the end of July, but that's nothing compared to the losses we've seen from biotech stocks.
In fact, this week's latest pullback has many biotech stocks in bear market territory.
Here's just how far they've fallen...
Start the conversation